STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
The discovery that a fugitive had been working under an alias in the biotech industry prompted a question: How did he evade scrutiny for two decades?
<p>The discovery that a fugitive had been working under an alias in the biotech industry prompted a question: How did he evade scrutiny for two decades?</p>